Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

CARM holding history

Carisma Therapeutics Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CARM overviewAll 13F holders of CARMFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of CARM by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−7,032−100.0%Sold outHolders
Q3 20257,032$1.93K<0.1%−15,073−68.2%ReducedHolders
Q2 202522,105$8.66K<0.1%+19,028+618.4%AddedHolders
Q1 20253,077$954<0.1%−21,224−87.3%ReducedHolders
Q4 202424,301$10.2K<0.1%+24,083+11,047.2%AddedHolders
Q3 2024218$214<0.1%−6−2.7%ReducedHolders
Q2 2024224$340<0.1%−26,979−99.2%ReducedHolders
Q1 202427,203$61.8K<0.1%−2,256−7.7%ReducedHolders
Q4 202329,459$86.3K<0.1%+14,634+98.7%AddedHolders
Q3 202314,825$62.7K<0.1%−578−3.8%ReducedHolders
Q2 202315,403$135.1K<0.1%+15,381+69,913.6%AddedHolders
Q1 202322$68<0.1%−491−95.7%ReducedConverted for a 1-for-20 splitHolders
Q4 202210,250$6.25K<0.1%−49,997−83.0%ReducedHolders
Q3 202260,247$26.0K<0.1%+59,497+7,932.9%AddedHolders
Q2 2022750$1.00K<0.1%−55,922−98.7%ReducedHolders
Q1 202256,672$34.0K<0.1%−36,975−39.5%ReducedHolders
Q4 202193,647$76.0K<0.1%+91,897+5,251.3%AddedHolders
Q3 20211,750$1.00K<0.1%−6,939−79.9%ReducedHolders
Q2 20218,689$40.0K<0.1%+5,939+216.0%AddedHolders
Q1 20212,750$7.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.